In a report issued on January 19, Eric Coldwell from Robert W. Baird maintained a Buy rating on Walgreens Boots Alliance (WBA – Research Report), with a price target of $70.00. The company’s shares closed last Thursday at $49.22.
According to TipRanks.com, Coldwell is a 5-star analyst with an average return of 13.5% and a 61.5% success rate. Coldwell covers the Healthcare sector, focusing on stocks such as Quest Diagnostics, AmerisourceBergen, and Cardinal Health.
Currently, the analyst consensus on Walgreens Boots Alliance is a Hold with an average price target of $55.00.
The company has a one-year high of $57.05 and a one-year low of $43.62. Currently, Walgreens Boots Alliance has an average volume of 6.18M.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of WBA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Retail pharmacy leader Walgreens Boots Alliance (NASDAQ:WBA) operates through its namesake brand Walgreens in the U.S. and Boots in the U.K. In addition, it owns retail and business brands including the No7 Beauty Company, Duane Reade, Ahumada in Chile, and Benavides in Mexico. The company also targets equity investments in healthcare, pharmacy, and retail and has a presence in over 25 countries with more than 450,000 employees.
Read More on WBA:
- Robert W. Baird Maintains a Hold Rating on CVS Health (CVS)
- Robert W. Baird Maintains a Hold Rating on Trex Company (TREX)
- Robert W. Baird Maintains a Hold Rating on Fortune Brands (FBHS)
- Robert W. Baird Maintains Their Buy Rating on Syneos Health (SYNH)
- Quest Diagnostics (DGX) Gets a Hold Rating from Robert W. Baird